论文部分内容阅读
为了探讨脐带组织来源的间充质干细胞(UC-MSC)免疫治疗特发性血小板减少性紫癜(ITP)的临床应用可能性,体外建立UC-MSC与ITP脾切除患者的脾脏单个核细胞共培养体系,用酶联免疫吸附试验(ELISA)法检测共培养上清液中IgG型抗血小板抗体(PAIgG)含量的变化。同时,用Brdu法研究UC-MSC对其中部分ITP患者血小板反应性T辅助淋巴细胞增殖的调节作用。结果表明,UC-MSC在体外试验中可刺激ITP患者脾细胞自发性释放PAIgG;UC-MSC在低剂量时(1∶100)抑制血小板诱导释放PAIgG;在高剂量(1:10)转为刺激作用。另外,UC-MSC还能抑制血小板反应性T辅助细胞的增殖,并呈一定的量效关系。结论:UC-MSC可体外影响ITP患者释放PAIgG,具体调控机制及临床应用价值有待深入研究。
To investigate the clinical application of umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) in immunotherapy of idiopathic thrombocytopenic purpura (ITP), we established co-culture of splenic mononuclear cells from UC-MSC and ITP splenectomy in vitro System, the change of IgG anti-platelet antibody (PAIgG) in co-culture supernatant was detected by enzyme linked immunosorbent assay (ELISA). At the same time, Brdu method was used to study the regulatory effect of UC-MSC on the proliferation of platelet-reactive T helper lymphocytes in some patients with ITP. The results showed that UC-MSCs could stimulate the spontaneous release of PAIgG from splenocytes of ITP patients in vitro; UC-MSCs inhibited platelet-induced PAIgG release at low dose (1: 100) effect. In addition, UC-MSC also inhibited the proliferation of platelet-reactive T helper cells, and showed a certain dose-effect relationship. CONCLUSION: UC-MSCs can affect the release of PAIgG from patients with ITP in vitro. The specific regulation mechanism and clinical value need to be further studied.